-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
01 Enterprise situation analysis
01As of the end of October 2022, a total of 1127017 biomedical enterprises have been established across the country in 2022; Among them, 102533 new enterprises were added in October, an increase of -17.
55%
over the previous month.
From the perspective of the geographical distribution of new enterprises, the top ten provinces in the number of enterprises are Guangdong Province, Shandong Province, Beijing Municipality, Henan Province, Shanghai Municipality, Anhui Province, Jiangsu Province, Hunan Province, Sichuan Province and Zhejiang Province, accounting for 59.
43%
of the total number of new enterprises in the country.
The top ten cities in terms of number of enterprises are Beijing, Shanghai, Guangzhou, Chengdu, Shenzhen, Chongqing, Hangzhou, Jinan, Changsha and Wuhan, accounting for 27.
18%
of the total number of new enterprises in the country.
Table 1: Top 10 provinces and cities with new companies added in October
Source: Firestone Creation Industry Data Center
02 Analysis of industrial financing
02In October 2022, a total of 102 financing events occurred in the biomedical field across the country, with a cumulative amount of 6.
672 billion yuan, an increase of 29.
11% and a 44.
98%
increase in financing amount compared with the previous month.
In terms of the number of financings, equity financing and angel rounds had the most financing events, with 31 and 11 respectively
.
In terms of financing amount, strategic financing obtained the highest financing amount of 1.
490 billion yuan; secondly, the B round financing amount is also more prominent, with a financing amount of 955 million yuan
.
Table 2: Distribution of medical and health financing events in October
Source: Firestone Creation Industry Data Center
From the perspective of financing regions, the province with the largest distribution of financing events this month is Guangdong Province, with 25 financings
.
In terms of financing amount, Zhejiang Province is the most prominent, with a financing amount of 1.
454 billion yuan; secondly, Guangdong Province is also more prominent, with a financing amount of 1.
316 billion yuan
.
Table 3: Regional distribution of financing events in October
Source: Firestone Creation Industry Data Center
From the perspective of financing amount, there were 102 financing events this month, of which 30 were financing events with a single financing amount of more than 100 million yuan, with a total financing amount of about 6.
122 billion yuan, accounting for 91.
76%
of the total financing scale this month.
Figure 1: Distribution of financing amount in October Source: Firestone Creation Industry Data Center
03 Analysis of listed enterprises
03As of the end of October 2022, there were 1,364 listed biopharmaceutical companies in China, and 8 new listed biopharmaceutical companies were added
in October.
The market distribution is 3 listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange, 1 listed on the Growth Enterprise Market of the Shenzhen Stock Exchange, 2 listed on the Beijing Stock Exchange, and 2 listed on the main board of the Hong Kong Stock Exchange
.
The total market value of listed biomedical enterprises in China reached 11.
14 trillion yuan
.
Among them, there are 11 listed biomedical companies with a market value of more than 100 billion yuan, distributed in innovative drugs, medical devices, medical services and other fields
.
Table 4: Top 10 biopharmaceutical companies by market capitalization in October
Source: Firestone Creation Industry Data Center
Table 5: List of biomedical listed companies in October
Source: Firestone Creation Industry Data Center
Compared with the previous month, Yasen Industrial, Ebang Technology, Boke Biotechnology, Xingjiean and Huanglong Pharmaceutical increased significantly, of which the market value of Yasen Industry (832240) increased by 100.
21%, and the market value of Ebang Technology (873889) increased by 99.
20%; Starfish, ST Heas, Haiyuan Medical, Tianma Sinopharm and Emondi fell significantly, of which the market value of Starfish Connect (871738) fell by 56.
52%, and the market value of ST Heath (871107) fell by 54.
60%.
Table 6: The top five biopharmaceutical companies with gains and losses in October
Source: Firestone Creation Industry Data Center
04 Analysis of drug clinical trials
04In October 2022, a total of 201 products were approved for clinical trials nationwide, a decrease of 37.
6%
compared with the previous month.
Among them, there are 61 in the field of biological medicine, 3 in the field of traditional Chinese medicine, and 137 in the field of chemical medicine
.
From the perspective of clinical trial enterprises, the approved clinical trials this month came from 98 companies, of which Jiangsu Weikel Pharmaceutical Technology Co.
, Ltd.
was the most approved, with 8 clinical approvals
.
From the perspective of clinical trial stage, there are 76 phase I.
clinical trials, 32 phase II clinical trials, 30 phase III clinical trials, and 3 phase IV clinical trials
.
Table 7: New phase III clinical trials were conducted in October
Source: Firestone Creation Industry Data Center
05 Analysis of drug approval
05In October 2022, a total of 42 products were approved for listing across the country, a decrease of 23.
6%
compared with the previous month.
It produces 42 drugs in China and imports 0 drugs
.
From the perspective of drug types, there are 0 in the field of biological medicine, 0 in the field of traditional Chinese medicine, and 42 in the field of chemical medicine
.
This month, the State Medical Products Administration approved a total of 2 new drugs on the market, of which 0 are Class 1 new drugs
.
Table 8: New drugs approved for marketing by the State Medical Products Administration in October
Source: Firestone Creation Industry Data Center
This month, two medicines were included in the priority review process
by CDE.
Table 9: Varieties approved by the CDE for priority review in October
Source: Firestone Creation Industry Data Center
06 Analysis of medical device approval
06In October 2022, a total of 1,213 medical devices were approved for the first time in China, including 1,094 Chinese-made devices and 119 imported devices
.
From the perspective of product registration classification, there are 159 Class III medical devices, 455 Class II medical devices, and 599 Class I medical devices
.
From the perspective of the geographical distribution of approved products, the top ten provinces approved for the three types of devices are Jiangsu Province, Guangdong Province, Shandong Province, Beijing Municipality, Zhejiang Province, Tianjin City, Shanghai City, Henan Province, Hubei Province and Chongqing City, accounting for 90.
84%
of the total number of new three types of device products in the country.
The top ten cities approved for Class 3 devices are Suzhou, Shenzhen, Beijing, Tianjin, Shanghai, Guangzhou, Zhengzhou, Changzhou, Ningbo and Nanjing, accounting for 61.
83%
of the total number of new Class 3 devices in the country.
Table 10: Top 10 provinces and cities with medical devices approved for the first time in October 2022
Source: Firestone Creation Industry Data Center
In October 2022, a total of 4 products entered the priority approval channel, and a total of 9 products entered the special review and approval channel
.
Table 11: Products approved for priority and special approval in October
Source: Firestone Creation Industry Data Center
